anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches

Clicks: 241
ID: 234505
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Many carcinogen- and human papilloma virus (HPV)-associated head and neck cancers (HNSCC) display a hematopoietic cell infiltrate indicative of a T-cell inflamed phenotype and an underlying anti-tumor immune response. However, by definition, these tumors have escaped immune elimination and formed a clinically significant malignancy. A number of both genetic and environmental mechanisms may allow such immune escape, including selection of poorly antigenic cancer cell subsets, tumor produced proinflammatory and immunosuppressive cytokines, recruitment of immunosuppressive immune cell subsets into the tumor and expression of checkpoint pathway components that limit T-cell responses. Here, we explore concepts of antigenicity and immunogenicity in solid tumors, summarize the scientific and clinical data that supports the use of immunotherapeutic approaches in patients with head and neck cancer, and discuss immune-based treatment approaches currently in clinical trials.
Reference Key
allen2015cancersanti-tumor Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Clint T. Allen;Paul E. Clavijo;Carter Van Waes;Zhong Chen
Journal The Journal of investigative dermatology
Year 2015
DOI
10.3390/cancers7040900
URL
http://www.mdpi.com/2072-6694/7/4/0900
Keywords
vaccines innate immunity immunogenicity immunosuppression checkpoint inhibitors adaptive immunity Oncology antigenicity including cancer and carcinogens tumors immunotherapyneoplasms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.